Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine EC vs Salofalk in moderate active Crohn's disease
2004-004083-77Phase 3Completed
- Sponsor
- Disphar
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Salcrozine in Crohn's disease (2 arms), sponsored by Disphar. Primary endpoint: Clinical remission rate. Started Dec 2004; status: completed.
02
Drugs
Salcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2004-004083-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004083-77.